account_id none on file
legal_name Elicio Therapeutics, Inc.
ticker ELTX
cik 1601485
domain elicio.com
linkedin_company_url https://www.linkedin.com/company/elicio-therapeutics-01
entry_point_account_id none on file
name Elicio Therapeutics Inc.
exchange Nasdaq
sector Health Care
sector index/company/sector/health-care/
calls 0 filings 6 executives 1 family 0
why_nownone on file
callsnone on file
filings
These increases will likely include increases related to the hiring of additional personnel and legal, regulatory and other fees and services associated with maintaining compliance with the Nasdaq Marketplace Rules or the Nasdaq Listing Rules and SEC requirements, accounting and audit fees, director and officer insurance costs and investor relations costs associated with being a public company.
filing / Aug 13, 2026 / receipt
If we are unable to raise capital, we will need to delay, reduce or terminate planned activities to reduce costs. Components of Results of Operations The following discussion summarizes the key factors our management believes are necessary for an understanding of our financial statements.
filing / Aug 13, 2026 / receipt
We may also consider steps to reduce our operating expenses. There can be no assurances that we will be successful in any of the foregoing.
filing / Aug 13, 2026 / receipt
These increases will likely include increases related to the hiring of additional personnel and legal, regulatory and other fees and services associated with maintaining compliance with the Nasdaq Marketplace Rules or the Nasdaq Listing Rules and SEC requirements, accounting and audit fees, director and officer insurance costs and investor relations costs associated with being a public company.
filing / May 11, 2026 / receipt
If we are unable to raise capital, we will need to delay, reduce or terminate planned activities to reduce costs. 22 Table of Contents Components of Results of Operations The following discussion summarizes the key factors our management believes are necessary for an understanding of our financial statements.
filing / May 11, 2026 / receipt
We may also consider steps to reduce our operating expenses. There can be no assurances that we will be successful in any of the foregoing.
filing / May 11, 2026 / receipt
executives
| Robert Connelly | Chief Executive Officer | - | receipt |
familynone on file
upcoming
| 2026-11-12 | earnings call | scheduled | ir |
changes
| 2024-10-17 | Principal Accounting Officer, appointed | sec_8k |
mcp_package_hint
slug elicio-therapeutics-inc
listing_url https://steadybase.io/company/data/index.json
mcp_url https://mcp.steadybase.io/mcp
steadybase-$